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Abstract
Objective: Betahistine is a histamine H1-receptor agonist and H3-receptor antagonist that is administered to treat Menie `re’s
disease. Despite widespread use, its pharmacological mode of action has not been entirely elucidated. This study
investigated the effect of betahistine on guinea pigs at dosages corresponding to clinically used doses for cochlear
microcirculation.
Methods: Thirty healthy Dunkin-Hartley guinea pigs were randomly assigned to five groups to receive betahistine
dihydrochloride in a dose of 1,000 mg/kg b. w. (milligram per kilogram body weight), 0.100 mg/kg b. w., 0.010 mg/kg b. w.,
0.001 mg/kg b. w. in NaCl 0.9% or NaCl 0.9% alone as placebo. Cochlear blood flow and mean arterial pressure were
continuously monitored by intravital fluorescence microscopy and invasive blood pressure measurements 3 minutes before
and 15 minutes after administration of betahistine.
Results: When betahistine was administered in a dose of 1.000 mg/kg b. w. cochlear blood flow was increased to a peak
value of 1.340 arbitrary units (SD: 0.246; range: 0.933–1.546 arb. units) compared to baseline (p,0.05; Two Way Repeated
Measures ANOVA/Bonferroni t-test). The lowest dosage of 0.001 mg/kg b. w. betahistine or NaCl 0.9% had the same effect
as placebo. Nonlinear regression revealed that there was a sigmoid correlation between increase in blood flow and dosages.
Conclusions: Betahistine has a dose-dependent effect on the increase of blood flow in cochlear capillaries. The effects of the
dosage range of betahistine on cochlear microcirculation corresponded well to clinically used single dosages to treat
Menie `re’s disease. Our data suggest that the improved effects of higher doses of betahistine in the treatment of Menie `re’s
disease might be due to a corresponding increase of cochlear blood flow.
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Introduction
In 1861 Prosper Menie `re (1799–1862) described a typical
combination of symptoms (hearing loss, tinnitus, and attacks of
vertigo) [1]. Only years later Jean-Martin Charcot (1825–1893)
named the disorder in his honor ‘‘Menie `re’s triad’’. Menie `re
ascribed the condition to a lesion in the semicircular canals,
thereby challenging the then prevailing opinion that vertigo was a
condition caused exclusively by pathologies of the central nervous
system [2]. Despite considerable research in this field since the
time of Menie `re, the malady still causes a high burden of disease
with an estimated lifetime prevalence of 0.51% [3]. Moreover,
there is still no consensus on its pathophysiology or treatment.
A wide range of treatment strategies is now applied; however,
reliable evidence of their efficacy is scarce for most of them, and
their side effects are severe. They include diuretics [4], intratym-
panic application of gentamicin [5], steroids [6] or endolymphatic
sac surgery [7].
Another option for long-term treatment is the oral administra-
tion of betahistine, a structural analog of histamine that has strong
antagonistic effects on histamine H3 receptors and weak agonistic
effects on histamine H1 receptors [8,9]. Its mechanism of action is
not yet fully understood. Clinical trials and meta-analyses suggest
that betahistine might have a beneficial effect on patients with
Menie `re `s disease, especially on the frequency of attacks [10,11,12].
An open trial found that this effect might be dose dependent: a
dosage of 48 mg tid (three times a day, i.e. 144 mg per day), was
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recently even higher dosages of 240 to 480 mg per day had a
significant effect on the frequency of attacks [14]. Nevertheless,
there is still a lack of well-conducted, controlled, double-blind
randomized prospective clinical trials on the application of
betahistine in Menie `re’s disease.
To date, several animal studies have shown that betahistine
promotes cochlear blood flow in vivo [15,16,17,18,19]. The
dosage of betahistine administered intravenously in these studies
ranged from 0.1 to 10.0 mg/kg b. w. None of these studies found a
dose-response curve. Corresponding doses for clinical use range
from about 0.05 mg/kg b. w. to 0.6 mg/kg b. w. orally [12,13,14].
Due to the drug’s delayed bioavailability during enteral resorption
and strong first-pass effect, the resulting serum concentration after
oral betahistine is estimated to be much lower than from
intravenous application. Thus, much higher doses need to be
given orally to achieve comparable plasma concentrations. In the
current study, we examined i. v. dosages calculated to correspond
to oral dosages given to patients. They ranged from 0.001 to
1,000 mg betahistine/kg b. w.
The aim of this study was to evaluate the effects of clinically
relevant dosages of betahistine on the microcirculation of cochlear
lateral wall vessels in order to elucidate the drug’s possible mode of
action in Menie `re’s disease.
Materials and Methods
Ethics Statement
All experiments were performed according to Bavarian state
regulations for animal experimentation and were approved on 18/
04/2011 by the responsible authorities, the District Government
of Upper Bavaria (Regierung von Oberbayern Munich, Germany;
animal license no.: 55.2-1-54-2532-131-10).
Animals
Thirty healthy female Dunkin-Hartley guinea pigs (250–400 g)
obtained from Charles River Laboratories (Sulzfeld, Germany)
were included in the study. The animals were first sedated for 10
minutes with 1 l O2/min, 0.5 l N2H/min with 2 Vol-% halothane
in a small plastic chamber before the induction of anaesthesia.
They then received an intraperitoneal injection of 50.0 mg/kg b.
w. ketamine and 5.0 mg/kg b. w. xylazine. Anaesthesia was
continued throughout the experiments with intraperitoneal
injections of 25.0 mg/kg b. w. ketamine and 2.5 mg/kg b. w.
xylazine given every 30 min.
The preparative surgery in the experiments lasted on average
about 1K h and the measurements 18 minutes. Following the
experiments, the animals were euthanized.
Surgical Preparation and Intravital Imaging
Surgical preparation and intravital microscopy for measuring
microcirculation parameters were performed as described else-
where [20]. Heart rate and oxygen saturation were continuously
monitored using pulsoxymetry. A fiberoptic pressure transducer
was placed in the left femoral artery for blood pressure
measurement (see below) and in the left jugular vein for
intravenous injections. Through a post auricular incision, the
right auditory bulla was opened, the cochlea itself was exposed,
and a rectangular window (0.260.3 mm) was incised at the second
turn.
Subsequently, intravital microscopy allowed direct observation
of cochlear lateral wall vessels and the measurement of red blood
cell velocity v (in mm/s) and vessel diameter (in mm). Fluorescein
isothiocyanate (FITC)-labeled dextran (molecular weight 500,000;
0.05–0.1 ml of a 5% solution in0.9% NaCl; Sigma, Deisenhofen,
Germany) was injected intravenously as a plasma marker to
differentiate plasma from red blood cells, which do not absorb the
dye. Selective observation of FITC-labeled plasma was performed
using epi-illumination with a 100 W mercury lamp attached to a
specific fluorescence filter block (excitation 450–490 nm, emission
515 nm), mounted on a modified Zeiss microscope (Axiotech-
Vario; Zeiss, Goettingen, Germany). Images were acquired by
video camera (C2400-08; Hamamatsu, Herrsching, Germany) and
recorded on digital video tape (Sony DVCAM DSV 45 P; Sony,
Cologne, Germany) for subsequent analysis. Red blood cell
velocity v [mm/s] and vessel diameter d [mm] were measured
off-line using an image analysis system (Cap Image; Zeintl,
Heidelberg, Germany), described in detail elsewhere [21]. For the
current study cochlear blood flow was assessed at a given point of
time in three independent vessels chosen for analysis and was
averaged. A line-shift diagram for each vessel allowed calculation
of red blood cell velocity v for 7 s [mm/s], while the average of
three independent measurements provided vessel diameter d [mm].
To quantify blood volume per time flowing through chosen
vessels, cochlear blood flow q (in pl/s) was calculated from these
parameters by the formula described by Baker and Wayland [22]:
q=(v/1.6) * (d/2)
2 * p. To correct for differences due to the
varying size of vessels within the cochlear window, cochlear blood
flow is reported as an arbitrary unit (arb. unit), reflecting relative
change from basal blood flow in each vessel.
Systemic Measurement of Blood Pressure
Mean arterial pressure was assessed by a fiberoptic pressure
catheter system (Samba Preclin, Samba Sensors AB, Va ¨straFro ¨-
lunda, Sweden) [23]. A pressure transducer with a diameter of
0.42 mm (Samba Preclin 420 transducer, 5 cm bare fiber length)
was inserted during microsurgery into the left femoral artery under
anaesthesia. Data acquisition took place by a Samba 201 Control
Unit; the Samba 200 Software Package was then used for analysis.
Blood pressure was measured in millimetres of mercury (mmHg).
To correct for values between different animals due to measure-
ment inaccuracy and individual factors, mean arterial pressure is
reported as an arbitrary unit (arb. unit), reflecting relative change
from basal pressure.
Treatment Protocol
Six animals were randomly assigned to 5 groups for treatment
with 4 different concentrations of betahistine dihydrochloride
(B4638, Sigma Aldrich, St. Louis, MO, USA) and to one control
group that received NaCl 0.9% as placebo. All groups underwent
identical surgery as described above. Baseline measurements of
cochlear blood flow and mean arterial pressure were initiated.
After 3 minutes either placebo or a dedicated concentration of
betahistine was infused for 2 minutes. Cochlear blood flow and
mean arterial pressure were continuously monitored from the
onset of baseline measurements for a total of 18 minutes.
Calculation of Corresponding Dosages for Oral
Medication
In order to extrapolate our conclusions to the clinical situation,
in which betahistine is administered orally, we calculated the
serum levels of betahistine achieved after intravenous administra-
tion to guinea pigs and compared them to the known maximum
plasma concentrations of 2-pyridylacetic acid achieved after oral
administration to humans [24,25]. 2-Pyridylacetic acid is a major
metabolite of betahistine that results after the first-pass effect. It is
commonly used as a measure of the betahistine pharmacokinetics,
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betahistine serum levels directly. Chen et. al. reported that
339.4 ng/ml was the maximum plasma concentration (Cmax) after
intake of a single dose of 24 mg betahistine [25]. An ideal guinea
pig with 0.250 kg b. w. and about 12 ml blood plasma was
estimated to reach this plasma concentration immediately after
intravenous infusion of 0.0163 mg/kg b. w.
Statistical Analysis
Statistical analyses were carried out by SigmaPlot 2004 for
Windows Version 9.01 (Systat Software, Chicago, IL, USA). To
detect significant differences, Two Way Repeated Measures
ANOVA (with time set as repeated factor) was used to compare
measurements at each time point from the treatment groups to the
same time point of the placebo group.
Correction for multiple testing was performed for testing over
multiple groups and multiple consecutive timepoints by Bonferroni
t-test. A P-value of a ,0.05 was considered to be statistically
significant.
Nonlinear regression was used to fit a curve using selected data
points. Results of nonlinear regression are reported as predicted
residual sums of squares statistic (PRESS) and Kolmogorov-
Smirnoff (K–S) Statistic Dn. The fit was assessed by Adjusted R-
squared R
2.
Results
The Effect of Betahistine on Cochlear Microcirculation
Administration of 0.001 and 0.010 mg betahistine/kg b. w. did
not lead to significant changes in blood flow (Figure 1A, Figure 1B).
The treatment group receiving 0.100 mg betahistine/kg b. w.
showed elevated cochlear perfusion after several minutes. Com-
pared to placebo values, perfusion was significantly augmented
during minutes 6 to 9 (p,0.05; Two Way RM ANOVA/
Bonferroni t-test). Subsequently there was a further decrease in
cochlear blood flow, but no more significant differences were
observed (Figure 1C).
The effect on cochlear microcirculation was most pronounced
in the treatment group receiving betahistine in a dosage of
1.000 mg/kg b. w. Here, cochlear blood flow showed a steep
increase up to a mean peak value of 1.340 arb. units (SD: 0.246;
range: 0.933–1.546 arb. units) at minute 10. This was significantly
different from placebo values from minute 8 on (p,0.05; Two
Way RM ANOVA/Bonferroni t-test). After reaching a peak value,
cochlear blood flow decreased, and from minute 14 on there was
no longer a significant difference from placebo values (Figure 1D).
Surprisingly, the administration of higher dosages of betahistine
led to an initial drop in cochlear blood flow. This was less distinct
when 0.10 mg/kg b. w. betahistine was dispensed (Figure 1C). A
marked drop in cochlear blood flow took place almost immediately
during infusion of 1.000 mg/kg b. w. betahistine (Figure 1D). At
minute 5, cochlear blood flow was significantly reduced to
0.818 arb. units (SD: 0.336; range: 0.600–1.488 arb. units;
p=0.002; Two Way RM ANOVA/Bonferroni t-test).
Effect of Betahistine on Systemic Blood Pressure
A basal mean arterial pressure (MAP) of 35.96 mmHg was the
average of all animals tested (n=30; SD: 7.76; range: 17.42–
56.00 mmHg). After treatment with betahistine, dose-dependent
changes were noted in MAP when compared to placebo.
Treatment groups receiving 0.01 and 0.001 mg betahistine/kg
b. w. showed no noticeably significant differences in systemic
blood pressure from the placebo group at any time point
(Figures 1A and 1B).
A dosage of 0.100 mg/kg b. w. betahistine led to a MAP that
peaked at 42.97 mmHg (SD: 6.66; range: 38.07–51.59 mmHg) or
1.373 from basal MAP at minute 7 (Figure 1C). This finding and
the values at minute 8 and 9 were significantly different from
placebo (p,0.05; Two Way RM ANOVA/Bonferroni t-test).
In the group treated with the highest dose of betahistine
(1.000 mg/kg b. w.), a sharp increase in MAP was observed which
reached a maximum of 64.10 mmHg (SD: 13.20; range: 47.76–
78.56 mmHg) at minute 11. This is equivalent to a relative change
to 1.523 arb. units compared to a mean basal MAP of this group.
Compared to the control group the values from minute 10 to 14
were statistically significant (p,0.05; Two Way RM ANOVA/
Bonferroni t-test). Thereafter the MAP decreased until the end of
the recording period (Figure 1D).
Like cochlear blood flow, the MAP also significantly decreased
after intravenous administration of 1.000 mg/kg b. w. betahistine
from minute 4 on; 33.09 mmHg was the minimal turning point at
minute 5 (SD: 5.21; range: 26.92–37.92 mmHg; Figure 1D). This
corresponds to a fraction of 0.727 from mean basal MAP of this
group. The difference from the placebo group was statistically
significant from minute 5 to 7 (p,0.05; Two Way RM ANOVA/
Bonferroni t-test).
Regression Analysis and Calculated Equivalent Oral
Dosage in Humans
A sigmoid curve was fitted by nonlinear regression of the peak
values of cochlear blood flow, thereby suggesting a saturation
effect for doses greater than 0.1 mg/kg b. w. (PRESS=0.0059;
Dn=0.2231 with significance level=0.9726). The fit was assessed
by Adjusted R-squared with R
2 =0.9996 (SD=0.0025), implying
a good approximation of the given variables by the fitted curve.
The corresponding dosage for oral administration to humans
was calculated as described above: a dose of 16 mg betahistine
orally corresponded to intravenous administration of 0.0109 mg/
kg b. w., 24 mg to 0.0163 mg/kg b. w., 48 mg to 0.0259 mg/kg b.
w. and 160 mg to 0.1086 mg/kg b. w., respectively. Figure 2
shows that these dosages lie within a range in which a steep dose-
dependent increase of cochlear blood flow was found after
increased administration of betahistine.
Discussion
The major findings of this study were as follows: betahistine has
a dose-dependent augmentative effect on both cochlear blood flow
and systemic blood pressure. Several groups have already
examined the effects of intravenous betahistine on inner ear
microcirculation [15,16,17,18,19] and reported an increase of
cochlear or vestibular blood flow. Our data are in line with the
previously reported results, but with three major differences. First,
the earlier experiments generally applied laser Doppler flowmetry
to quantify cochlear blood flow; however, it does not readily allow
conclusions to be drawn on blood flow changes in the capillaries of
the cochlear lateral wall. Second, the dosages administered in
animal studies before were not the doses used in the treatment of
Menie `re’s disease: they were much higher. Third, none of the
earlier studies found a sigmoid dose-response curve.
Laser Doppler flowmetry has been used to quantify cochlear
microcirculation since the 1980s [26,27,28,29]. An alternative
technique, which is – as discussed below - more elaborate, is
intravital flourescence microscopy, which was applied in this
study. It relies on direct observation of cochlear lateral wall
vessels [20,30,31,32,33] and was more appropriate for the
present investigation, since intravital flourescence microscopy
allows direct measurement of blood flow exclusively in
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flowmetry, which also gives a good estimation of blood flow in
the cochlea, is in fact an average signal of any vessel beneath
the Doppler probe, including among others the spiral modiolar
artery and vessels of the bony capsule that belong to middle ear
circulation [31,34].
Our current understanding of the pathophysiology of
Menie `re’s disease is that a relative overproduction of endolymph
occurs in the membranous labyrinth of the inner ear with
periodical rupture or leakage of Reissner’s membrane
[35,36,37]. The mode of action of betahistine in Menie `re’s
disease is that it probably increases inner ear blood flow and
thereby reduces endolymphatic hydrops by shifting the balance
of production and re-absorption of endolymph toward absorp-
tion. Since the capillaries of the cochlear lateral wall are the
main location of cochlear metabolism, the present study focused
solely on these vessels, thereby contributing to the understand-
ing of blood flow regulation by betahistine.
To date, betahistine has been administered intravenously in
every animal model used to investigate the effect of betahistine
on inner ear microcirculation [15,16,17,18,19]. Clinically it is
only administered orally. This leads to different pharmacoki-
netics, since enteral absorption is followed by a considerably
decelerated bioavailability. Additionally, a strong first-pass effect
of betahistine has to be taken into account. To be able to
compare animal studies with clinical studies using oral
administration, we calculated the plasma concentration of
betahistine achieved by intravenous injection of guinea pigs
and designed the present study according to the results. The
data presented here taken together with the pharmacokinetic of
betahistine in human test persons [24,25] leads to the
conclusion that a further increase in cochlear perfusion in
patients suffering from Menie `re’s disease might be achieved by
doses higher than currently applied. While this calculation
allows only a very rough estimation of plasma concentrations,
we believe that it is much more instructive than directly
comparing dosage administered via oral intake versus intrave-
nous administration as in earlier experimental concepts. In the
past, dosages of 4 mg four times a day and up to 24 mg three
times a day were considered effective [12]. Our data suggest
that higher doses might have an even more pronounced effect
on cochlear perfusion. Two clinical trials support our view; they
found that the dosages of 48 mg tid are more effective than 16
or 24 mg tid [13] and even higher dosages of 160 mg tid [14]
are even more effective. Additionally, time Tmax from oral
administration to peak concentration has been shown to be
0.79 h (SD: 0.32 h) to 0.98 (SD: 0.47) in healthy volunteers
[24,25]. Assuming that Menie `re’s disease can be treated by
betahistine through increasing cochlear perfusion and thereby
reducing a causative endolymphatic hydrops, we conclude that
either high doses of up to 160 mg tid or more frequent
administration of betahistine could be advantageous for patients.
This is currently being evaluated in an ongoing clinical trial.
Figure 1. Cochlear blood flow and mean arterial blood flow over time before and after infusion of betahistine. A: Betahistine
0.001 mg/kg b. w.; B: Betahistine 0.010 mg/kg b. w.; C: Betahistine 0.100 mg/kg b. w.; D: Betahistine 1.000 mg/kg b. w.; arbitrary units, mean 6 SD, *:
p,0.05.
doi:10.1371/journal.pone.0039086.g001
Figure 2. Peak values of cochlear blood flow with curve fitted by nonlinear regression and calculated corresponding oral dosage.
Four treatment groups as described in the text; peak mean 6 SD; *: p,0.05.
doi:10.1371/journal.pone.0039086.g002
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effective doses increases blood flow in cochlear stria vascularis
vessels in a dose-dependent sigmoid way and thus is recommended
for the treatment of Menie `re’s disease.
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